Published Oct 25, 2026, 1:30 PM ET · Updated 18 days ago · 2 sources
Moderna and Merck melanoma trial data positive, but Wall Street reacted negatively
Youtube
·
Original Report
Oncologists cheered breakthrough melanoma trial data from Moderna and Merck, showing a 42% reduction in tumor recurrence, but Wall Street reacted negatively, causing both companies' shares to fall, with Moderna's stock plunging 17%.